Physicochemical Properties
Molecular Formula | C24H16CLN3O |
Molecular Weight | 397.86 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | VEGFR2 42.5 nM (IC50) |
ln Vitro | VEGFR-2-IN-58 inhibits the proliferation of HepG2, MCF-7, A549, HT-29, PC3 and WI-38 cells with IC50 values of 7.28, 6.72, 6.66, 8.51, 14.5 and 30 μM, respectively[1]. In addition to inducing apoptosis, VEGFR-2-IN-58 (8.51 μM, 24 h) also exhibited G2/M phase cell growth inhibition in the HT-29 cell line [1]. VEGFR-2-IN-58 (0.85, 4.26 μM, 48 h) exhibited significant inhibition of wound healing in HT-29 cells[1]. |
Cell Assay |
Western Blot Analysis[1] Cell Types: HT-29 cells Tested Tested Concentrations: 0.85,4.26, 8.51 μM Incubation Duration: 24 h Experimental Results: Reduced p-VEGFR-2 expression in a dose-dependent manner. Cell Cycle Analysis[1] Cell Types: HT-29 cells Tested Tested Concentrations: 8.51 μM Incubation Duration: 24 h Experimental Results: Caused cell growth arrest at G2/M based on accumulation of DNA content inHT-29 cells. Apoptosis Analysis[1] Cell Types: HT-29 cells Tested Tested Concentrations: 8.51 μM Incubation Duration: 24 h Experimental Results: Elevated apoptotic gene BAX expression and suppressed anti-apoptotic gene Bcl-2 expression. Elevated total apoptosis percentage. |
References |
[1]. Furan- and Furopyrimidine-Based Derivatives: Synthesis, VEGFR-2 Inhibition, and In Vitro Cytotoxicity. ACS Med Chem Lett. 2024 Nov 25;15(12):2150-2157. |
Solubility Data
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5134 mL | 12.5672 mL | 25.1345 mL | |
5 mM | 0.5027 mL | 2.5134 mL | 5.0269 mL | |
10 mM | 0.2513 mL | 1.2567 mL | 2.5134 mL |